These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39210071)

  • 1. Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study.
    Pane M; Stanca G; Coratti G; D' Amico A; Sansone VA; Berti B; Fanelli L; Albamonte E; Ausili Cefaro C; Cerchiari A; Catteruccia M; De Sanctis R; Leone D; Palermo C; Buchignani B; Onesimo R; Kuczynska EM; Tosi M; Pera MC; Bravetti C; Tiziano FD; Bertini E; Mercuri E
    Eur J Pediatr; 2024 Nov; 183(11):4735-4745. PubMed ID: 39210071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies.
    Alves BKAMF; Araujo APQC; Santos FND; Ribeiro MG
    Arq Neuropsiquiatr; 2024 Nov; 82(11):1-8. PubMed ID: 39505005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.
    Goedeker NL; Rogers A; Fisher M; Arya K; Brandsema JF; Farah H; Farrar MA; Felker MV; Gibbons M; Hamid OA; Harmelink M; Herbert K; Kichula E; King K; Lakhotia A; Lee BH; Kuntz NL; Parsons J; Rehborg R; Veerapaniyan A; Zaidman CM
    Muscle Nerve; 2024 Dec; 70(6):1247-1256. PubMed ID: 39370660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal natural history of type I spinal muscular atrophy: a critical review.
    Mercuri E; Lucibello S; Perulli M; Coratti G; de Sanctis R; Pera MC; Pane M; Montes J; de Vivo DC; Darras BT; Kolb SJ; Finkel RS
    Orphanet J Rare Dis; 2020 Apr; 15(1):84. PubMed ID: 32248834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study.
    van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
    Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
    J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life.
    Steffens P; Weiss D; Perez A; Appel M; Weber P; Weiss C; Stoltenburg C; Ehinger U; von der Hagen M; Schallner J; Claussen B; Lode I; Hahn A; Schuler R; Ruß L; Ziegler A; Denecke J; Johannsen J
    Eur J Paediatr Neurol; 2024 Jul; 51():17-23. PubMed ID: 38772209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene.
    Zarkov M; Stojadinović A; Sekulić S; Barjaktarović I; Perić S; Keković G; Drasković B; Stević Z
    Vojnosanit Pregl; 2015 Oct; 72(10):859-63. PubMed ID: 26665550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded.
    Coratti G; Bovis F; Pera MC; Civitello M; Rohwer A; Salmin F; Glanzman AM; Montes J; Pasternak A; De Sanctis R; Dunaway Young S; Duong T; Mizzoni I; Milev E; Sframeli M; Morando S; Albamonte E; D'Amico A; Catteruccia M; Brolatti N; Pane M; Scoto M; Messina S; Escudero JE; De Waele L; Hirano M; Zolkipli-Cunningham Z; Darras BT; Bertini E; Nascimiento Osorio A; Bruno C; Goemans N; Sansone VA; Day J; Baranello G; Muntoni F; Finkel R; Mercuri E;
    Eur J Neurol; 2024 Dec; 31(12):e16517. PubMed ID: 39392101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feeding difficulties in children and adolescents with spinal muscular atrophy type 2.
    Wadman RI; De Amicis R; Brusa C; Battezzati A; Bertoli S; Davis T; Main M; Manzur A; Mastella C; Munot P; Imbrigiotta N; Schottlaender L; Sarkozy A; Trucco F; Baranello G; Scoto M; Muntoni F
    Neuromuscul Disord; 2021 Feb; 31(2):101-112. PubMed ID: 33454188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.
    Kariyawasam DS; D'Silva AM; Sampaio H; Briggs N; Herbert K; Wiley V; Farrar MA
    Lancet Child Adolesc Health; 2023 Mar; 7(3):159-170. PubMed ID: 36669516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I SMA "new natural history": long-term data in nusinersen-treated patients.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Brigati G; Tacchetti P; Salmin F; De Sanctis R; Lucibello S; Pera MC; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Clin Transl Neurol; 2021 Mar; 8(3):548-557. PubMed ID: 33547876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy.
    Ma K; Zhang K; Chen D; Wang C; Abdalla M; Zhang H; Tian R; Liu Y; Song L; Zhang X; Liu F; Liu G; Wang D
    Hum Mol Genet; 2024 Jun; 33(13):1120-1130. PubMed ID: 38520738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
    Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
    N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy.
    De Sanctis R; Pane M; Coratti G; Palermo C; Leone D; Pera MC; Abiusi E; Fiori S; Forcina N; Fanelli L; Lucibello S; Mazzone ES; Tiziano FD; Mercuri E
    Neuromuscul Disord; 2018 Jan; 28(1):24-28. PubMed ID: 29174525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina.
    Medrano S; Monges S; Gravina LP; Alías L; Mozzoni J; Aráoz HV; Bernal S; Moresco A; Chertkoff L; Tizzano E
    Eur J Paediatr Neurol; 2016 Nov; 20(6):910-917. PubMed ID: 27510309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.